Issue: January 2013
December 14, 2012
3 min read
Save

Gains persist in vaccination coverage of Alaska Natives, American Indians

Issue: January 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recent gains in immunizations among Alaska Native and American Indian populations have not slowed, according to data published recently by the CDC.

Perspective from Molly Howell, MPH

CDC researchers reported information from National Immunization Surveys that included data from 2006 to 2010. The data indicated that although disparities exist between white and American Indian/Alaska Native (AI/AN) populations in 2001 to 2004, the findings from the latest surveys show the discrepancies are disappearing.

Amy V. Groom, MPH, of the Immunization Services Division, National Center for Immunization and Respiratory Diseases at CDC, and researchers said overall vaccination coverage was similar between the two groups in most years, with slightly lower coverage rates with four or more doses of pneumococcal conjugate vaccine among AI/AN children in 2008 and 2009 and 2006 and 2009. However, when stratified by geographic regions, “AI/AN children had coverage that was similar to or higher than that of white children for most vaccines in most years studied.”

Vaccination coverage assessed in this study included four or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids, or diphtheria and tetanus toxoids and any acellular pertussis vaccine (4+DTaP); three or more doses of poliovirus vaccine (3+polio); one or more doses of measles, mumps, and rubella (1+MMR) vaccine; three or more doses of Haemophilus influenzae type b (3+Hib) vaccine; three or more doses of hepatitis B (3+HepB) vaccine; one or more doses of varicella (1+Var) vaccine; and four or more doses of pneumococcal conjugate (4+PCV) vaccine.

The researchers also examined coverage with the combined 4+DTaP; 3+polio; 1+MMR; 3+Hib; 3+HepB; and 1+Var vaccine series, referred to as the 4:3:1:3:3:1 series and coverage with this series plus 4+PCV, referred to as the 4:3:1:3:3:1:4 series.

In addition, they also analyzed coverage for these two series without Hib vaccine (4:3:1:x:3:1, 4:3:1:x:3:1:4) because of the Hib vaccine shortage from 2007 to 2009.

Disclosure: Groom reports no relevant financial disclosures.